All articles tagged with #molecular glues
Recent research has expanded the understanding of molecular glue degraders, revealing that they can target a much wider array of proteins than previously thought, including those with surface features beyond the beta-hairpin loop motif, opening new possibilities for drug development against previously 'untouchable' proteins.
A recent study describes a new compound, IBG1, which effectively degrades BRD4, a protein associated with cancer, independently of the previously targeted protein DCAF15. The compound recruits the CRL4-DCAF16 complex to degrade BRD4, and it enhances the affinity of DCAF16 for BRD4. The study also reveals that IBG1 bivalently binds both bromodomains of BRD4, and it selectively degrades BRD2 and BRD4 but not BRD3. These findings provide insights into a potential new approach for targeted protein degradation in cancer therapy.
St. Jude Children's Research Hospital scientists have developed SJ3149, a potent and selective CK1α degrader, which acts as a "molecular super-glue" by targeting cancer-related proteins for destruction through proteasomal degradation. This compound shows broad anti-cancer activity and may offer a new therapeutic approach for previously undruggable proteins. The research provides a platform for the discovery of novel molecular glues for cancer treatments and offers potential for developing new options for treating different pediatric cancers.